
Customize View
Recently disclosed strategic alliances only (within the last two years)
Include Strategic Alliances for:Current subsidiaries



Strategic Alliances

Recently Disclosed Strategic Alliances
Strategic Alliance Name
Primary Industry
Source
ATAI Life Sciences AG
Biotechnology
Key DevelopmentStrategic Alliances Nov-11-2019
Business Description: ATAI Life Sciences AG operates as a clinical-stage biopharmaceutical company. The company engages in developing various therapeutic candidates that are focused on multiple mental health disorders. The companyâ€™s therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a GABA/nicotinic modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01 is a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was incorporated in 2018 and is based in Berlin, Germany with additional offices in New York and London. ATAI Life Sciences AG operates as a subsidiary of Atai Life Sciences N.V.
ENAMINE Ltd
Life Sciences Tools and Services
Key DevelopmentClient Announcements Nov-05-2019
Business Description: ENAMINE Ltd is a life sciences tools and services company. It is based in Ukraine.
*denotes proprietary relationship